A1184 - Tolerability and pharmacokinetic analyses of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone sensitive prostate cancer (mHSPC) from ARASENS. - Tombal, B.; Smith, M.R.; Hussain, M.; Saad, F.; Fizazi, K.; Sternberg, C.N.; Crawford, E.D.; Kapur, S.; Zhang, W.; Ploeger, B.; Li, R.; Kuss, I.; et al. (European Urology, 2023)